GSK Launches Cancer Research Consortium - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GSK Launches Cancer Research Consortium



GlaxoSmithKline has formed the Oncology Clinical and Translational Consortium (OCTC), a scientific research network comprised of six international cancer centers.  The center includes Gustave Roussy (Villejuif, France), the University of Texas MD Anderson Cancer Center (Houston, US), Memorial Sloan-Kettering Cancer Center (New York), Netherlands Cancer Institute (Amsterdam, the Netherlands), Princess Margaret Cancer Center, University Health Network (Toronto), and Vall d’Hebron Institute of Oncology (Barcelona).

In forming the consortium, GSK will gain OCTC’s knowledge in preclinical, translational, and clinical development of anticancer therapeutics including kinase inhibitors, epigenome-modulating compounds, and immunotherapies. The centers will have access to studies with GSK’s early-stage oncology pipeline and opportunities to advance oncology therapeutics.  OCTC will foster scientific collaboration among the members and GSK.

Consortium members were selected for their international leadership and expertise in oncology research.  Members will collaborate on processes to ensure the highest quality standards for the collection of biological samples as well as the conduct of biomarker and clinical research.  Projects driven through the OCTC will include Phase I and II single agent and novel combination trials with GSK’s targeted and immune therapies as well as translational and preclinical studies.

Source: GlaxoSmithKline

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here